vasodilator-stimulated phosphoprotein

a 46-50 kDa membrane protein from platelets & a wide variety of cells and tissues; a common substrate for cyclic nucleotide-dependent protein kinases; amino acid sequence given in second source

Also Known As:

Ena-VASP family proteins; VASP protein, human; Vasp protein, mouse; Vasp protein, rat; vasodilator-stimulated phosphoprotein,; vasodilator-stimulated phosphoprotein, mouse; vasodilator-stimulated phosphoprotein, rat

Networked: 119 relevant articles (4 outcomes, 16 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Wei, Lei: 10 articles (01/2019 - 10/2008)
2.	Alessi, Marie-Christine: 5 articles (12/2019 - 04/2008)
3.	Cuisset, Thomas: 5 articles (12/2019 - 04/2008)
4.	Rosenberger, Peter: 5 articles (01/2018 - 08/2007)
5.	Su, Ke: 5 articles (01/2015 - 12/2011)
6.	Walter, Ulrich: 5 articles (06/2011 - 07/2003)
7.	Gao, Yang: 4 articles (10/2021 - 01/2018)
8.	Pitari, Giovanni M: 4 articles (01/2021 - 06/2012)
9.	Wang, Ying: 4 articles (01/2019 - 12/2006)
10.	Tian, Yihao: 4 articles (08/2018 - 06/2012)

Related Diseases

1.	Thrombosis (Thrombus) 01/01/2023 - "PD assessments included VerifyNow P2Y12 reaction units (PRU), light transmittance aggregometry, vasodilator-stimulated phosphoprotein, and Total Thrombus-Formation Analysis System. " 10/01/2016 - "The analysis of the phosphorylation status of vasodilator-stimulated phosphoprotein by flow cytometry has shown a predictive value for adverse events and stent thrombosis. " 12/01/2007 - "The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis." 02/01/2010 - "Multiple electrode aggregometry predicts stent thrombosis better than the vasodilator-stimulated phosphoprotein phosphorylation assay." 10/15/2009 - "These patients had significantly greater ADP-Ag compared to patients free of stent thrombosis (68 +/- 14% vs 56 +/- 19%, p = 0.002) but only a trend toward a greater Platelet Reactivity Index of vasodilator-stimulated phosphoprotein (62 +/- 14% vs 53 +/- 23%, p = 0.19). "
2.	Wounds and Injuries (Trauma) 11/01/2020 - "CORM-3-treated rats displayed significant ameliorated depression- and anxiety-like behaviors, improved cerebral blood flow, and fractional anisotropy (FA), showed less neuronal pyroptosis and apoptosis in the amygdala, and upregulated the phosphorylation of Vasodilator-stimulated phosphoprotein (VASP) and ERK1/2. However, CORM-3 neuroprotective effects against trauma were only partially reversed by KT5823. " 08/01/2008 - "In this study, we tested the hypothesis that 17beta-estradiol (E2) administration after trauma-hemorrhage reduces lung injury through a mechanism involving estrogen receptor (ER)-dependent activation of the endothelial nitric oxide (NO) synthase (eNOS)/protein kinase G (PKG)/vasodilator-stimulated phosphoprotein (VASP) pathway. "
3.	Nephritis 04/01/2005 - "Vasodilator-stimulated phosphoprotein-deficient mice demonstrate increased platelet activation but improved renal endothelial preservation and regeneration in passive nephrotoxic nephritis."
4.	Cardiomegaly (Heart Hypertrophy) 03/01/2008 - "8beta-VE2 enhanced aortic ERbeta expression (+75.7 +/- 7.1%, P < 0.01 vs. placebo), improved NO-dependent vasorelaxation, augmented phosphorylation of the vasodilator-stimulated phosphoprotein in isolated aortic rings (P < 0.05 vs. placebo), increased cardiac output (+20.4 +/- 2.5%, P < 0.01 vs. placebo), and attenuated cardiac hypertrophy (-22.2 +/- 3.2%, p < 0.01 vs. placebo). "
5.	Acute Coronary Syndrome 01/01/2016 - "Onclopidogrel PR was detected by the original impedance whole blood platelet aggregation assay, modified assay, and flow cytometric vasodilator stimulated phosphoprotein (VASP) assay in 168 patients with acute coronary syndromes (ACS). " 11/01/2008 - "Flow cytometric assessment of vasodilator-stimulated phosphoprotein: prognostic value of recurrent cardiovascular events after acute coronary syndromes." 01/01/2013 - "A total of 444 patients with acute coronary syndromes treated with percutaneous coronary intervention and prasugrel 10 mg/day were monitored by measurement of the vasodilator-stimulated phosphoprotein (VASP) index 2 to 4 weeks after hospital discharge. " 08/01/2012 - "It was the study objective to determine whether glycaemic control affects the extent of platelet inhibition by thienopyridines as assessed by vasodilator-stimulated phosphoprotein flow cytometry (VASP-FCT) in patients with diabetes mellitus (DM) undergoing percutaneous coronary intervention (PCI) during acute coronary syndrome (ACS). " 12/01/2019 - "We aimed to evaluate the relationship between on-ticagrelor PR, assessed by the vasodilator-stimulated phosphoprotein index (VASP), and thrombotic and bleeding events in patients with acute coronary syndrome (ACS) treated by percutaneous coronary intervention (PCI). "

Related Drugs and Biologics

1.	Adenosine Diphosphate (ADP)
2.	Estrogen Receptor beta
3.	Neuroprotective Agents
4.	KT 5823
5.	Clopidogrel (Plavix)
6.	Ticagrelor
7.	Proteins (Proteins, Gene)
8.	Prasugrel Hydrochloride
9.	Cyclic GMP-Dependent Protein Kinases (Protein Kinase G)
10.	Cytochrome P-450 CYP2C19

Related Therapies and Procedures

1.	Stents
2.	Percutaneous Coronary Intervention
3.	Coronary Artery Bypass (Coronary Artery Bypass Surgery)
4.	Therapeutics
5.	Electrodes (Electrode)